R&D Tax Incentives Senior Analyst/Manager – Part Time
Swanson Reed is a leading firm in the area of R&D tax credits and innovation incentives. We service a diverse range of clients from technology start-ups to billion dollar ASX listed and Government Owned Corporations in the commercial aspects of research, development, management and technology transfer. Swanson Reed seeks to recruit an Analyst or Senior Analyst to join their energetic team.
This is an excellent opportunity to help shape small to large mining, manufacturing and construction companies with their commercially sensitive innovation agendas.
You will help structure R&D activities so a company may attain the maximum possible Government entitlements.
You will be accountable for the identification, analysis, structuring, costing, and submission of highly confidential R&D projects.
You will assist with the development of R&D plans and costings.
You will work with a vast array of company executives to solve their complex commercial problems.
You will receive on the job training and guided until you are fully competent.
You will possess tertiary qualifications in Accounting, Economics, Engineering, Science or similar.
2+ years experience in the mining, manufacturing, chemical, construction or general engineering sectors will be viewed favourably.
Professional servces experience and experiece in management of R&D tax credit claims is desired.
A self-starter with an inquisitive mind who demonstrates a committed and flexible approach complemented by exceptional relationship management skills will excel in this role.
The National Institute of Health (NIH) is investing $248.7 million in new technologies to address challenges associated with COVID-19 testing. NIH’s Rapid Acceleration of Diagnostics (RADx) initiative has awarded contracts to seven biomedical diagnostic companies to support a range of new lab-based and point-of-care tests that could significantly increase the number, [...]
Lung cancer is the leading cause of cancer-related deaths worldwide. Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancers and 60% of these have wild-type epidermal growth factor receptor (EGFR) mutations. [...]